The pending Tempus acquisition dominates the stock's trajectory; this earnings release is largely backward-looking with no guidance. Monitor the merger proxy/prospectus (S-4) for shareholder vote timing and any termination risk. The strong clinical revenue growth trajectory supports the strategic rationale for the deal.
How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5- T+0 · Nov 5 $15.55entry
- T+1 · 11d ago +1.54%α +1.23% · $15.79
- T+5 · 5d ago +1.99%α −1.30% · $15.86
- T+7 · todayOpen
- T+20 · in 17d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Personalis reported Q3 2026 total revenue of $25.6M, up 77% YoY from $14.5M, driven by clinical test revenue surging to $4.4M from $0.4M and population sequencing revenue of $4.0M vs $0.2M. Net loss widened to $33.8M from $21.7M, with SG&A expense doubling to $26.0M largely due to merger-related costs. The company withdrew guidance and will not hold an earnings call due to the pending Tempus acquisition announced July 20, 2026.
Key Financial Metrics
Key Facts
- Total revenue $25.6M vs $14.5M YoY (+77%)
- Clinical test revenue $4.4M vs $0.4M YoY, volume 13,157 tests vs 4,388
- Pharma testing services revenue $17.1M vs $13.1M YoY
- Population sequencing (VA MVP) revenue $4.0M vs $0.2M YoY
- SG&A expense $26.0M vs $13.0M YoY, including $4.8M related party sales/marketing
- Cash and investments $190.6M at quarter end
- Guidance withdrawn due to pending Tempus acquisition
Financial Impact
Revenue beat consensus by $4.3M (20.2%); EPS miss by $0.07 (28% worse than consensus); operating loss widened $12.2M YoY
Segment Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| Pharma testing services | $17.1M | +30.3% |
| Enterprise sales | $8.0K | -98.8% |
| Population sequencing | $4.1M | +1638.0% |
| Clinical diagnostic | $4.4M | +1039.1% |
| Other | $33.0K | -63.3% |
Risk Factors
- Merger may not close if shareholders do not approve or conditions are not satisfied
- Operating losses continue to widen with SG&A costs elevated
- No forward guidance provided, reducing visibility
- Potential litigation related to the merger
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-447196 |
| Document: psnl-20261104.htm | 0001193125-26-447196 |
| Document: 0001193125-26-447196-index-headers.html | 0001193125-26-447196 |
| Document: 0001193125-26-447196-index.html | 0001193125-26-447196 |
| Document: 0001193125-26-447196.txt | 0001193125-26-447196 |
| 8-K Data (Synthetic) | 0001193125-26-447196 |
Track record
29 reports on PSNL
4 of 6 bullish or bearish reports moved the stock their way by T+60. Best: +18.82% at T+60 after the Jul 20, 2026 report. 8 of 9 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $15.16 Now $14.80 −2.34% settles Feb 12
- Nov 13, 20263d ago SC 13G/A Neutral 2/10 Entry $15.71 Now $14.80 −5.79% settles Feb 11
- Nov 12, 20264d ago 425 Neutral 4/10 Entry $15.86 Now $14.80 −6.68% settles Feb 10
- Nov 6, 202610d ago 425 Neutral 3/10 Entry $15.95 Now $14.80 −7.21% settles Feb 5
- Nov 4, 202612d ago 8-K Neutral 5/10 Viewing Entry $15.55 Now $14.80 −4.82% settles Feb 3
- Nov 3, 202613d ago 425 Neutral 3/10 Entry $15.79 Now $14.80 −6.27% settles Feb 2
- Oct 30, 202617d ago 425 Neutral 4/10 Entry $15.76 Now $14.80 −6.09% settles Jan 29
- Oct 21, 202626d ago DEFM14A Neutral 5/10 Entry $15.82 Now $14.80 −6.45% settles Jan 20
- Oct 20, 202627d ago 425 Neutral 4/10 Entry $15.90 Now $14.80 −6.92% settles Jan 19
- Oct 20, 202627d ago 425 Neutral 5/10 Entry $15.90 Now $14.80 −6.92% settles Jan 19
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers